SuperValu Cruises past Analyst Expectations, Still Sinks

SuperValu (SVU) reported adjusted EPS of $0.46, beating the consensus by $0.10. Total sales from continuing operations stood at $3.8 billion—35% higher YoY.

Kinder Morgan’s 3Q17 Results Met Analysts' Expectations

Kinder Morgan reported its 3Q17 results on October 18, 2017. It reported an adjusted EPS of $0.15, which was in-line with analysts’ consensus estimates.

Pre-Market Report: Global Markets Are Stable on October 20

On October 20, the Shanghai Composite Index closed at 3,378.65 after rising 0.25%. The SPDR S&P China ETF (GXC) fell 1.7% on October 19, 2017.

Highs and Lows: Wall Street's Performance on October 19

After rising for five consecutive trading weeks, the S&P 500 started this week on a stronger note. It rose in the first three trading days of the week.


Who's Watching Exelixis Now?

Ten analysts were covering Exelixis in October 2017. One analyst suggested a “strong buy,” and five analysts suggested a “buy” rating.

Who's Watching Alexion Now?

In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals’ (ALXN) Soliris.

How Rite Aid Performed in 2Q17

Rite Aid (RAD) reported results for 2Q17 on Thursday, September 28, 2017. The company reported a loss of one cent per share on total sales of $7.7 billion.

GlaxoSmithKline’s Latest Developments and Valuation

On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.

Abbott Stock Rides High on Recent Product Approvals

Abbott Laboratories (ABT) was trading at its 52-week high of $54.75 on September 29, 2017.

Medtronic: Poised to Leverage Cardiac Space in Fiscal 2018

Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.

Eli Lilly’s Latest Developments and Valuation

On September 25, 2017, Geisinger entered into an agreement with Boehringer Ingelheim on behalf of Eli Lilly to develop a risk-prediction model for three serious health consequences associated with type 2 diabetes.

The Key Near-Term Growth Drivers for Medtronic in Fiscal 2018

According to Medtronic (MDT), ~85% of the patients in the US who use pacemakers opt for a dual-chambered device. In fiscal 1Q18, Medtronic reported robust demand for its single-chamber pacemaker, Micra.

Thermo Fisher Scientific: 'Strong Buy' Ratings and Key Drivers

Let’s take a look at Wall Street analysts’ recommendations and 12-month target prices for Thermo Fisher Scientific (TMO).

Boston Scientific’s Product Launches Boost Investor Confidence

On September 25, Boston Scientific (BSX) announced the launch of the Resonate family of ICD and CRT-D systems. The devices are approved by the FDA for conditional use in the MRI environment.

Bristol-Myers Squibb’s Latest Developments and Valuation

Headquartered in New York City, Bristol-Myers Squibb (BMY) is a US pharmaceutical company that includes products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises.

Investor Update: A Look at Johnson & Johnson's Key Developments

On September 15, 2017, Johnson & Johnson announced a collaboration with the Department of Health and Human Services to develop a portfolio of drugs and vaccines for influenza and other infectious disease threats.

What Investors Can Expect from Medtronic

In fiscal 1Q18, Medtronic (MDT) reported revenues close to $7.4 billion, which is a 3% year-over-year (or YoY) increase.

Why Most Analysts Recommend a 'Buy' for Varian Medical Systems

With its recent spin-off of Varex Imaging (VREX), Varian Medical Systems (VAR) has established itself as a focused cancer management medical technology company.

What Allergan's Latest Developments Tell Us

On September 19, 2017, Allergan’s Allure received three 2017 Best of the Beauty Breakthrough awards.

Dentsply Sirona: Its Partnerships and Collaborations

According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”

Roche's Drugs, Trials, and FDA Approvals after 1H17

In the first half of 2017, Roche’s (RHHBY) Tecentriq reported revenues of CHF 237.0 million. In that period, the US market for Tecentriq generated revenues of CHF 229.0 million.

Key Updates on ZBH Stock for Investors

On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.

Pfizer Unveiled: Latest Developments, Valuation

On September 1, 2017, the FDA approved Pfizer’s drug Mylotarg (gemtuzumab ozogamicin) for the treatment of CD33-positive acute myeloid leukemia.

Novo Nordisk and How It's Positioned after the 1st Half of 2017

In the first half of 2017, Novo Nordisk (NVO) reported revenues of $8.3 billion compared to $8.2 billion in the first half of 2016. In 2Q17, it generated revenues of $4.2 billion.


Please select a profession that best describes you: